Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54


Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer.

Reebye V, Huang KW, Lin V, Jarvis S, Cutilas P, Dorman S, Ciriello S, Andrikakou P, Voutila J, Saetrom P, Mintz PJ, Reccia I, Rossi JJ, Huber H, Habib R, Kostomitsopoulos N, Blakey DC, Habib NA.

Oncogene. 2018 Jun;37(24):3216-3228. doi: 10.1038/s41388-018-0126-2. Epub 2018 Mar 7.


Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer.

Voutila J, Reebye V, Roberts TC, Protopapa P, Andrikakou P, Blakey DC, Habib R, Huber H, Saetrom P, Rossi JJ, Habib NA.

Mol Ther. 2017 Dec 6;25(12):2705-2714. doi: 10.1016/j.ymthe.2017.07.018. Epub 2017 Aug 4.


Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.

Ross SJ, Revenko AS, Hanson LL, Ellston R, Staniszewska A, Whalley N, Pandey SK, Revill M, Rooney C, Buckett LK, Klein SK, Hudson K, Monia BP, Zinda M, Blakey DC, Lyne PD, Macleod AR.

Sci Transl Med. 2017 Jun 14;9(394). pii: eaal5253. doi: 10.1126/scitranslmed.aal5253. Erratum in: Sci Transl Med. 2017 Jul 26;9(400):.


AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.

Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MV, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR.

Sci Transl Med. 2015 Nov 18;7(314):314ra185. doi: 10.1126/scitranslmed.aac5272.


Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signaling.

Michaud NR, Wang Y, McEachern KA, Jordan JJ, Mazzola AM, Hernandez A, Jalla S, Chesebrough JW, Hynes MJ, Belmonte MA, Wang L, Kang JS, Jovanovic J, Laing N, Jenkins DW, Hurt E, Liang M, Frantz C, Hollingsworth RE, Simeone DM, Blakey DC, Bedian V.

Mol Cancer Ther. 2014 Feb;13(2):386-98. doi: 10.1158/1535-7163.MCT-13-0420. Epub 2013 Dec 16.


Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.

Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, Barry ST, Gabizon A, Grodzinski P, Blakey DC.

Cancer Res. 2013 Apr 15;73(8):2412-7. doi: 10.1158/0008-5472.CAN-12-4561. Epub 2013 Feb 19.


A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo.

Eberlein C, Kendrew J, McDaid K, Alfred A, Kang JS, Jacobs VN, Ross SJ, Rooney C, Smith NR, Rinkenberger J, Cao A, Churchman A, Marshall JF, Weir HM, Bedian V, Blakey DC, Foltz IN, Barry ST.

Oncogene. 2013 Sep 12;32(37):4406-16. doi: 10.1038/onc.2012.460. Epub 2012 Oct 29.


MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo.

Jenkins DW, Ross S, Veldman-Jones M, Foltz IN, Clavette BC, Manchulenko K, Eberlein C, Kendrew J, Petteruti P, Cho S, Damschroder M, Peng L, Baker D, Smith NR, Weir HM, Blakey DC, Bedian V, Barry ST.

Mol Cancer Ther. 2012 Aug;11(8):1650-60. doi: 10.1158/1535-7163.MCT-11-1027. Epub 2012 Jun 7.


An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand binding.

Kendrew J, Eberlein C, Hedberg B, McDaid K, Smith NR, Weir HM, Wedge SR, Blakey DC, Foltz I, Zhou J, Kang JS, Barry ST.

Mol Cancer Ther. 2011 May;10(5):770-83. doi: 10.1158/1535-7163.MCT-10-0876. Epub 2011 Mar 9.


Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.

Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, Blakey DC, Tabrizi M, Jallal B, Trail PA, Coats S, Bosslet K, Chang YS.

Cancer Res. 2011 Feb 1;71(3):1029-40. doi: 10.1158/0008-5472.CAN-10-2274. Epub 2011 Jan 18.


A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models.

Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, Wen S, Zhou JQ, Tabrizi M, Emery S, McDermott B, Pablo L, McCoon P, Bedian V, Blakey DC.

Mol Cancer Ther. 2010 Jan;9(1):145-56. doi: 10.1158/1535-7163.MCT-09-0554. Epub 2010 Jan 6.


Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma.

Fens MH, Hill KJ, Issa J, Ashton SE, Westwood FR, Blakey DC, Storm G, Ryan AJ, Schiffelers RM.

Br J Cancer. 2008 Oct 21;99(8):1256-64. doi: 10.1038/sj.bjc.6604675. Epub 2008 Sep 16.


Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging.

Robinson SP, Kalber TL, Howe FA, McIntyre DJ, Griffiths JR, Blakey DC, Whittaker L, Ryan AJ, Waterton JC.

Neoplasia. 2005 May;7(5):466-74.


Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.

Goto H, Yano S, Matsumori Y, Ogawa H, Blakey DC, Sone S.

Clin Cancer Res. 2004 Nov 15;10(22):7671-6.


Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.

Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, Langmuir P, Wheeler C, Stone A, Leadbetter J, Ryan AJ, Blakey DC, Waterton JC.

Clin Cancer Res. 2004 Jun 1;10(11):3650-7.


Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model.

McIntyre DJ, Robinson SP, Howe FA, Griffiths JR, Ryan AJ, Blakey DC, Peers IS, Waterton JC.

Neoplasia. 2004 Mar-Apr;6(2):150-7.


Anti-cancer drug discovery and development summit.

Blakey DC.

Expert Opin Investig Drugs. 2003 Sep;12(9):1577-82.


Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging.

Robinson SP, McIntyre DJ, Checkley D, Tessier JJ, Howe FA, Griffiths JR, Ashton SE, Ryan AJ, Blakey DC, Waterton JC.

Br J Cancer. 2003 May 19;88(10):1592-7.


The first international conference on vascular targeting: meeting overview.

Thorpe PE, Chaplin DJ, Blakey DC.

Cancer Res. 2003 Mar 1;63(5):1144-7.


ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.

Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, Hill SA.

Cancer Res. 2002 Dec 15;62(24):7247-53.


ZD6126: a novel small molecule vascular targeting agent.

Blakey DC, Ashton SE, Westwood FR, Walker M, Ryan AJ.

Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1497-502.


DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767.

Monks NR, Blakey DC, East SJ, Dowell RI, Calvete JA, Curtin NJ, Arris CE, Newell DR.

Eur J Cancer. 2002 Jul;38(11):1543-52.


Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice.

Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC, Sone S.

Cancer Res. 2002 Jul 1;62(13):3711-5.


Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.

Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ.

Clin Cancer Res. 2002 Jun;8(6):1974-83.


ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts.

Blakey DC, Burke PJ, Davies DH, Dowell RI, East SJ, Eckersley KP, Fitton JE, McDaid J, Melton RG, Niculescu-Duvaz IA, Pinder PE, Sharma SK, Wright AF, Springer CJ.

Cancer Res. 1996 Jul 15;56(14):3287-92.


New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide link.

Dowell RI, Springer CJ, Davies DH, Hadley EM, Burke PJ, Boyle FT, Melton RG, Connors TA, Blakey DC, Mauger AB.

J Med Chem. 1996 Mar 1;39(5):1100-5.


Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).

Springer CJ, Dowell R, Burke PJ, Hadley E, Davis DH, Blakey DC, Melton RG, Niculescu-Duvaz I.

J Med Chem. 1995 Dec 22;38(26):5051-65.


Antibody-directed enzyme prodrug therapy (ADEPT) for treatment of major solid tumour disease.

Blakey DC, Burke PJ, Davies DH, Dowell RI, Melton RG, Springer CJ, Wright AF.

Biochem Soc Trans. 1995 Nov;23(4):1047-50. No abstract available.


Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.

Blakey DC, Davies DH, Dowell RI, East SJ, Burke PJ, Sharma SK, Springer CJ, Mauger AB, Melton RG.

Br J Cancer. 1995 Nov;72(5):1083-8.


In vitro and in vivo comparison of a randomly coupled antibody fragment-enzyme conjugate with a site-specific conjugate.

Werlen RC, Offord RE, Blakey DC, East SJ, Melton RG, Rose K.

Biomed Pept Proteins Nucleic Acids. 1995;1(5):251-4.


Comparison of the cellular internalization of antibodies used either as immunotoxins or in ADEPT.

Blakey DC, Pinder PE, Wright AF.

Cell Biophys. 1994;24-25:175-83.


The interactions of protein inhibitors with tumour proteases studied in solution and immobilised on cell surfaces in frozen sections.

Steven FS, Anees M, Talbot IC, Blakey DC, Hasleton PS.

Anticancer Res. 1993 Nov-Dec;13(6A):2003-10.


Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug.

Blakey DC, Valcaccia BE, East S, Wright AF, Boyle FT, Springer CJ, Burke PJ, Melton RG, Bagshawe KD.

Cell Biophys. 1993 Jan-Jun;22(1-3):1-8.


Further evidence for different isoenzymic forms of a cell surface protease, guanidinobenzoatase, associated with tumours.

Steven FS, Griffin MM, Blakey DC, Talbot IC, Hanski C, Bell J.

Anticancer Res. 1992 Nov-Dec;12(6B):2159-64.


Drug targeting with monoclonal antibodies. A review.

Blakey DC.

Acta Oncol. 1992;31(1):91-7. Review.


Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cells.

Blakey DC, Skilleter DN, Price RJ, Watson GJ, Hart LI, Newell DR, Thorpe PE.

Cancer Res. 1988 Dec 15;48(24 Pt 1):7072-8.


Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.

Thorpe PE, Wallace PM, Knowles PP, Relf MG, Brown AN, Watson GJ, Blakey DC, Newell DR.

Cancer Res. 1988 Nov 15;48(22):6396-403.


Uptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver parenchymal and non-parenchymal cells in vitro and in vivo.

Blakey DC, Skilleter DN, Price RJ, Thorpe PE.

Biochim Biophys Acta. 1988 Feb 22;968(2):172-8.


Antibody toxin conjugates: a perspective.

Blakey DC, Wawrzynczak EJ, Wallace PM, Thorpe PE.

Prog Allergy. 1988;45:50-90. Review. No abstract available.


Prevention of carbohydrate-mediated clearance of ricin-containing immunotoxins by the liver.

Blakey DC, Thorpe PE.

Cancer Treat Res. 1988;37:457-73. Review. No abstract available.


Treatment of malignant disease and rheumatoid arthritis using ricin A-chain immunotoxins.

Blakey DC, Thorpe PE.

Scand J Rheumatol Suppl. 1988;76:279-87. Review. No abstract available.


New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.

Thorpe PE, Wallace PM, Knowles PP, Relf MG, Brown AN, Watson GJ, Knyba RE, Wawrzynczak EJ, Blakey DC.

Cancer Res. 1987 Nov 15;47(22):5924-31.


Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutants.

Thorpe PE, Blakey DC, Brown AN, Knowles PP, Knyba RE, Wallace PM, Watson GJ, Wawrzynczak EJ.

J Natl Cancer Inst. 1987 Nov;79(5):1101-12.



Blakey DC, Thorpe PE.

Bioessays. 1986 Jun;4(6):292-7. No abstract available.


Supplemental Content

Loading ...
Support Center